Stephen V Liu: No clear standard for NSCLC transformed to SCLC, despite high DLL3
Liu said a talk at MaTOSLung highlighted disappointing tarlatamab outcomes in transformed disease, despite high DLL3 expression, and welcomed ongoing studies in this population.
“no clear standard exists and huge unmet need”— Stephen V Liu, MD
Stephen V Liu, a thoracic oncologist, wrote on X on 21 November 2026 about a talk on non-small cell lung cancer (NSCLC) that has transformed to small cell lung cancer (SCLC). The talk was given at MaTOSLung by a speaker who posts as @drshieldsmd. Liu described it as a "great talk" on how to approach this setting.
According to Liu, transformed disease shows high expression of DLL3, but outcomes with tarlatamab have been disappointing.
Liu said he was pleased to see ongoing studies in this population. He wrote that no clear standard exists for these patients and that the unmet need is large.
Liu's X profile lists him as chief of haematology and oncology at Georgetown and MedStar Georgetown University Hospital, and head of developmental therapeutics at Lombardi Cancer Center.
Original source
“no clear standard exists and huge unmet need”
— Stephen V Liu, MD View the post on X